Are alternatives to ibrutinib/ibrutinib emerging?

With the advancement of medical technology, new treatment options are constantly emerging, bringing more hope to patients with chronic lymphocytic leukemia (CLL). In November 2019, the U.S. Food and Drug Administration (FDA) approved the marketing of a BTK inhibitor called Acalabrutinib. This move undoubtedly injected new vitality into the treatment field of CLL.

Ibrutinib/Ibrutinib, another BTK inhibitor, has achieved significant efficacy in such diseases. However, some patients may face treatment challenges due to intolerance to its toxicities. The emergence of acotinib provides new treatment possibilities for these patients. Because it has a different toxicity profile from ibrutinib, acotinib has been well tolerated and effective in patients who cannot tolerate ibrutinib.

Ina 2019 real-world study, researchers conducted an in-depth analysis of the actual effectiveness of acotinib in patients with CLL. The results showed that discontinuation rates with acotinib were relatively low among patients who could not tolerate ibrutinib. This finding further supports the potential of acotinib as an alternative to ibrutinib to improve patient tolerability and treatment outcomes.

However, it is important to note that each patient's specific situation is unique. Whether to use acotinib and how to use it need to be comprehensively considered based on the patient's specific condition, drug resistance, and personal health status. Therefore, the evaluation and advice of a professional doctor are crucial when formulating the best treatment plan.